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MaOBJECTIVES This study investigated whether patients with patent foramen ovale (PFO) have an increased risk of stroke
due to permanent pacemaker (PPM)/implantable cardioverter-deﬁbrillator (ICD) implantation.
BACKGROUND Data are lacking on the risk of stroke in patients with PFO and implantable intracardiac devices, either a
PPM or an ICD. We investigated whether patients with PFO have increased risk of stroke due to PPM/ICD implantation.
METHODS Between 2001 and 2008, 2,921 consecutive patients with PFO (67.5  16.4 years of age, 52.2% male) were
identiﬁed from our echocardiography database. These patients were divided into a device group (patients had PPM/ICD
implantation for any reason after receiving a diagnosis of PFO) and a no device group (patients did not have PPM or ICD
implantation). Patients who had PFO closure during follow-up were excluded. Both groups were matched for baseline
characteristics and medications. The incidence of ischemic stroke was assessed in each group after propensity score
matching (case:control ratio of 1:1 yielding 231 pairs). All patients completed at least 4 years of follow-up until May 2012.
RESULTS There were 2,690 patients in the n device group (67.3  16.4 years of age, 51.6% male) and 231 patients in
the device group (75.4  14.6 years of age, 59.3% male). Six patients (2.6%) in the no device group and 6 (2.6%) in the
device group had a stroke during the follow-up period. No difference in the rate of stroke, transient ischemic stroke, or
stroke/transient ischemic stroke was observed between the 2 groups.
CONCLUSIONS The risk of stroke in patients with PFO and an implantable intracardiac device is similar to those without
an intracardiac device. In patients with PFO, without a history of stroke, device implantation might not be considered
a risk factor for future stroke occurrence. (J Am Coll Cardiol Intv 2014;7:1221–6) © 2014 by the American College of
Cardiology Foundation.I mplantation of permanent pacemakers (PPMs)and intracardiac deﬁbrillators (ICDs) has steadilyincreased over the past 2 decades (1). Despite the
beneﬁts associated with device implantation, the risk
of thrombus formation on intracardiac devices is
a potential concern (2,3). Investigators have re-
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PFO = patent foramen ovale
PPM = permanent pacemaker
TIA = transient ischemic attack
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1222and/or the presence of an associated atrial
septal aneurysm have been associated with
an increased risk of stroke in patients with
PFO (16). Similarly, DeSimone et al. (17)
reported their experience with 3 patients
who presented with lead thrombus, PFO,
and stroke, presumably due to paradoxical
embolism.Although the risk of cryptogenic stroke in patients
with lead thrombosis and PFO is physiologically
plausible, to our knowledge, there has been no
systematic evaluation to study the effect of device
implantation on stroke outcomes in a population
consisting of only PFO patients. We compared the
incidence of ischemic stroke in PFO patients with or
without device implantation from our large institu-
tional database.
METHODS
In this retrospective study, we identiﬁed patients
with a diagnosis of PFO at the Cleveland Clinic either
by transesophageal echocardiography (TEE), trans-
thoracic echocardiography, or both between 2001 and
2008. Patients were then stratiﬁed by the presence or
absence of PPM or ICD. The date of PFO diagnosis was
considered the entry date for each patient in the
study. Patients who had a history of stroke or tran-
sient ischemic attack (TIA) were excluded. Patients
who had closure of PFO during the follow-up period
were excluded from the study, unless they ex-
perienced a stroke/TIA before the closure procedure.
We used electronic medical records to collect de-
mographic information, baseline clinical characteris-
tics, medical history, medications, and laboratory test
results.
Patients were followed until the end of 2012 or until
the primary endpoint, whichever occurred earlier. The
primary endpoint was any ischemic stroke event dur-
ing the follow-up period. Ischemic stroke was deﬁned
as the sudden onset of focal neurological deﬁcit lasting
>24 h with evidence of infarct documented on radio-
logical investigation. Transient neurological dysfunc-
tion lasting <24 h and without evidence of infarction
on radiological investigation was identiﬁed as a
TIA. Any suspected cerebrovascular event was inves-
tigated using TEE along with computed tomography/
magnetic resonance imaging; Doppler and color
duplex examination of the extracranial carotid,
vertebral, and basal intracranial arteries; echocardi-
ography and Holter echocardiography; contrast
transthoracic echocardiography and TEE; and neces-
sary laboratory investigation. Permission for the study
was obtained from the institutional review board.STATISTICAL ANALYSIS. Statistical analyses were
performed using SPSS 20.0 statistical package for
Windows (IBM, Chicago, Illinois). Continuous data
are expressed as mean  SD, whereas categorical data
are presented as a percentage. The chi-square test
was used for comparison of categorical variables, and
an independent t test was used to compare contin-
uous variables. A p value <0.05 was considered
signiﬁcant for all statistical purposes.
Considering device implantation as the dependent
variable, a propensity score was generated for each
patient through a regression model using variables
listed in Table 1. Each patient in the device group was
matched to a patient in the no device group based on
the closest propensity score. The method yielded 2
matched groups with 231 patients each (Figure 1). A
time-to-event model was used to analyze the stroke
outcome, and time of device implantation was
considered as the time-varying covariate. The iden-
tiﬁcation of PFO was considered as time zero for all
the patients. Ischemic stroke, TIA, and the combined
outcome were compared between the 2 groups using
the chi-square test.
RESULTS
A total of 2,921 patients were included; 231 patients
who received a PPM or ICD during the follow-up
period were included in the device group and 2,690
patients who did not receive a PPM or ICD were
included in the no device group. Propensity score
matching yielded 1:1 matched groups from the total
population.
Before propensity score matching, patients in the
device group were older and were more often male
(Table 1). Atrialﬁbrillation (58.9%vs. 28.7%, p<0.001),
mitral regurgitation (23.4% vs. 13.9%, p < 0.001), and
heart failure (HF) (55.4% vs. 17.5%, p < 0.001) were
more common in the device group, and the average
ejection fractionwas lower in device group (40.41% vs.
52.47%, p < 0.001). There were also signiﬁcant
differences in medication use, with patients in the
device group receiving more medications compared
with patients in the no device group (Table 1). After
propensity score matching, the 2 groups (n ¼ 231
patients each) were identical with equivalent baseline
characteristics and medications.
Ischemic stroke occurred in 6 patients in each
group (Table 2). The primary outcome was not
different between the 2 groups (2.6% vs. 2.6%,
p ¼ 1.0). The event rate for stroke was 3.03 events/
1,000 patient-years in the no device group and 2.82
events/1,000 patient-years in the device group. The
time-to-event analysis showed that there was no
TABLE 1 Baseline Characteristics Between the 2 Groups








(n ¼ 231) p Value
Age, yrs 75.39  14.58 67.27  16.36 <0.001 75.39  14.58 76.87  12.86 0.25
Male 137 (59.3) 1389 (51.6) 0.03 137 (59.3) 134 (58.0) 0.85
Atrial ﬁbrillation 136 (58.9) 771 (28.7) <0.001 136 (58.9) 128 (55.4) 0.51
Hypertension 107 (46.3) 1,103 (41.0) 0.13 107 (46.3) 111 (48.1) 0.78
Diabetes 91 (39.4) 654 (24.3) <0.001 91 (39.4) 84 (36.4) 0.57
Smoking history 99 (42.9) 995 (37.0) 0.09 99 (42.9) 107 (46.3) 0.51
Dyslipidemia 86 (37.7) 919 (34.2) 0.35 86 (37.7) 74 (32.0) 0.28
COPD 21 (9.1) 227 (8.4) 0.71 21 (9.1) 22 (9.5) 1.00
Migraine 5 (2.2) 135 (5.0) 0.05 5 (2.2) 5 (2.2) 1.00
Atrial septal aneurysm 18 (7.8) 272 (10.1) 0.30 18 (7.8) 13 (5.6) 0.46
Heart failure 128 (55.4) 47 (17.5) <0.001 128 (55.4) 122 (52.8) 0.64
Ejection fraction 40.41  16.94 52.47  11.46 <0.001 40.41  16.94 40.13  15.80 0.85
Creatinine 1.21  0.62 1.13  1.03 0.27 1.21  0.62 1.21  0.62 0.66
Aortic stenosis 5 (2.2) 22 (0.8) 0.06 5 (2.2) 7 (3.0) 0.77
Mitral regurgitation 54 (23.4) 374 (13.9) <0.001 54 (23.4) 51 (22.1) 0.82
Aspirin 155 (67.1) 1,581 (58.8) 0.01 155 (67.1) 151 (65.4) 0.77
Clopidogrel 43 (18.6) 430 (16.0) 0.31 43 (18.6) 48 (20.8) 0.64
Beta-blockers 172 (74.5) 1,511 (56.2) <0.001 172 (74.5) 175 (75.8) 0.83
ACE inhibitor 166 (71.9) 1,256 (46.7) <0.001 166 (71.9) 171 (74.0) 0.68
Insulin 57 (24.7) 385 (14.3) <0.001 57 (24.7) 47 (20.3) 0.32
Warfarin 146 (63.2) 1,112 (41.3) <0.001 146 (63.2) 144 (62.3) 0.92
Statin 132 (57.1) 1,187 (44.1) <0.001 132 (57.1) 124 (53.7) 0.51
Values are mean  SD or n (%).
ACE ¼ angiotensin-converting enzyme; COPD ¼ chronic obstructive pulmonary disease.
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1223difference in stroke outcome between the 2 groups
(p ¼ 0.748; odds ratio: 0.342; 95% conﬁdence inter-
val: 0.003 to 3.833). In patients who had a stroke
(12 patients), the annual event rate was 0.33 events/
year in the no device group, whereas it was
0.20 events/year for patients in the device group.
Further analysis in the matched cohort showed
that of 22 events (stroke and TIA), 19 occurred in
patients with atrial ﬁbrillation. Subgroup analysis in
patients with atrial ﬁbrillation revealed that 10 pa-
tients in the device group experienced a neurological
event compared with 9 patients in the no device
group (7.4% vs. 7.0%, p ¼ 1.00). In patients who did
not have atrial ﬁbrillation, no ischemic stroke event
occurred after device implantation, whereas the
event rate in the no device group was found to be 2.22
events/1,000 patient-years.
DISCUSSION
In our study, we found that implantation of an
electrical cardiac device with an electrode in the
right ventricle was not related to an increase in the
incidence of stroke. PPM and ICD implantation
has increased steadily, with >350,000 devicesplaced per year in the United States alone (18). As
mentioned previously, device implantation can be
complicated by thrombus formation on the lead, due
to either thrombogenic properties associated with
the lead or local vascular stenosis predisposing to
thrombus formation at the site (19). PFO may be
considered as an additional risk in the presence of
an implanted device. Although PFO has been asso-
ciated with cryptogenic stroke, data concerning
the association of PFO with stroke is conﬂicting
(5,6,10,12,13,20). Nevertheless, given the frequency
of PFO in the general population and the substantial
number of patients undergoing cardiac device im-
plantation, the theoretical risk of lead thrombus
formation leading to paradoxical embolism and
stroke is not insigniﬁcant. The current literature in
this regard is limited to a few case reports (21). We
therefore believe that our retrospective analysis of a
large group of patients undergoing device implan-
tation, demonstrating that the presence of PFO
did not increase the risk of stroke, is an important
contribution.
DeSimone et al. (22) performed a retrospective study
of 6,075 patientswith an implanted device (364 PFOvs.
5,711 non-PFO patients). They concluded that patients
FIGURE 1 Standardized Difference of Baseline Characteristics and Discharge
Medication Between the 2 Groups Before and After Propensity Score Matching
Using device implantation as the dependent variable, a propensity score was generated for
each patient through a regression model using variables listed in Table 1. Each patient in
the device group was matched to a patient in the no device group based on the closest
propensity score. The method yielded 1:1 matched groups from the total population.
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1224with PFO have a signiﬁcantly higher stroke/TIA inci-
dence compared with patients without PFO (8.2% vs.
2.0%, p < 0.0001). Our study differs from theirs in few
important ways. First, our patient population consists
of PFO patients only, as we want to speciﬁcally study
whether device implantation has any impact on stroke
outcome in patients with the defect. Second, they
included patients with previous stroke/TIA, whereas
we did not because previous stroke itself is an impor-
tant predictor of future stroke (23).
We also considered many other baseline variables,
including medications in our study. We believe that
this detailed information is imperative because
medications taken by patients are certainly important
with regard to stroke outcomes. The role of statin
therapy in the prevention of stroke has been widely
studied (24). Also, meta-analysis done to compare the
stroke outcome between medical therapy and PFO
closure have not shown medical therapy to offer





(n ¼ 231) p Value
Ischemic stroke 6 (2.6) 6 (2.6) 1.00
TIA/ischemic stroke 10 (4.3) 12 (5.2) 0.83
Values are n (%).
TIA ¼ transient ischemic attack.study even showed medical therapy to be comparably
efﬁcacious to PFO closure (30). Overall, it can be said
that the difference in medications between the 2
groups may affect the stroke outcomes. However, the
medications taken by patients in our study group
were identical, and the results of our study may
also be attributed to comparable medical treatment
between the 2 matched groups.
Interestingly, of a total of 22 cerebrovascular
ischemic events in our population, 19 occurred in
patients with atrial ﬁbrillation. The association of
atrial ﬁbrillation with stroke is well established. Also,
investigators have demonstrated the presence of
undetected intermittent atrial ﬁbrillation in patients
with stroke (31–35). Hence, atrial ﬁbrillation, and not
device implantation, seems to be the most probable
reason for a stroke event in our patient population.
The incidence of atrial ﬁbrillation and the use
of anticoagulant medication were identical in our
matched groups. This is an important message for
operators evaluating patients for PFO closure in the
setting of stroke and reminds clinicians of the need
for a thorough evaluation for causes of stroke
and appropriate medication therapy for patients
with PFO.
The overall incidence of the primary outcome
measure was fairly low in our study. Among patients
with PFO and previous stroke, other investigators
have demonstrated a stroke/TIA recurrence rate of as
high as 19% at 4 years, which is 2 to 3 times the risk
of patients without PFO (12,36). Because we included
only those patients who did not have a previous
stroke/TIA, there is a possibility that the ischemic
event rate in our population was too low to detect a
difference between patients with and without an
implantable cardiac device. Further studies need to
be performed to draw a deﬁnitive conclusion.
STUDY LIMITATIONS. The limitations associated
with any retrospective study apply to this analysis,
including selection bias and differences in unad-
justed baseline characteristics. Correction for these
factors using propensity score matching was per-
formed, but is not equivalent to a true randomization.
It is important to note that, before propensity
matching, patients in the device group were receiving
more aggressive antithrombotic therapy and other
medications (warfarin, aspirin, statin). This differ-
ence is a limitation when comparing the risk of
thromboembolic complications. Worse clinical char-
acteristics (e.g., atrial ﬁbrillation, age, heart failure,
low ejection fraction) and medication use are likely to
be associated with patients who require a device
implantation. However, propensity score matching
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1225yielded 2 groups with identical baseline and medica-
tion characteristics.
Second, we excluded the patients who had an
implanted device but also underwent PFO closure
during the follow-up period, apart from those who
had any stroke/TIA before the closure. It is possible
that high-risk patients may have beneﬁted from
closure to offset the risk of any event. To minimize
the same, we included only those patients who had
no history of a neurological event. The inclusion of
patients who had an event before the closure was
done to minimize possible selection bias. Overall, our
study was mainly limited to only those PFO patients
who were receiving medical therapy, and it needs to
be viewed accordingly.
Another limitation of our study is the low event
rate. Our strict exclusion criteria may well have
accounted for low number of events in our study
group. We limited our study to the majority of
patients who may not be considered high risk andthus presents a dilemma for interventionalists con-
cerning the decision to close the PFO. In the presence
of these limitations, further studies from larger
centers, collaborative studies, or possibly a random-
ized trial may produce more deﬁnite answers.
CONCLUSIONS
In patients with PFO and no previous episode of an
ischemic neurological event, implantation of a PPM or
ICD is not associated with an increased risk of an
ischemic stroke event in the subsequent 4 years.
Evaluation for other stroke risk factors, including
atrial ﬁbrillation, is imperative to reduce the risk of
neurological events.
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